Table 1. Baseline characteristics of the study group.

	All patients (n=3,157)	Nonsurvivors (n=137)	Survivors (n=3,020)	p-value
Age (years)	65 (56–73)	73 (63–83)	65 (56–73)	<0.001
Male gender, n (%)	2,087 (66.1)	73 (53.3)	2,014 (66.7)	0.002
Hypertension, n (%)	1,864 (59)	91 (66.4)	1,773 (58.7)	0.076
Diabetes mellitus, n (%)	1,184 (37.5)	55 (40.1)	1,129 (37.4)	0.528
Dyslipidemia, n (%)	1,120 (35.5)	46 (33.6)	1,074 (35.6)	0.715
Smoking, n (%)	1,179 (61.9)	79 (57.6)	1,876 (62.1)	0.043
Family history of CAD, n (%)	1,101 (34.9)	37 (27.2)	1,064 (35.8)	0.043
CAD, n (%)	1,446 (45.8)	74 (54)	1,372 (45.4)	0.054
PAD, n (%)	122 (3.9)	6 (4.4)	116 (3.8)	0.005
AF, n (%)	483 (15.3)	34 (24.8)	449 (14.9)	0.004
Heart failure, n (%)	978 (31)	76 (55.5)	902 (29.9)	<0.001
Stroke history, n (%)	142 (4.5)	11 (8)	131 (4.3)	0.086
Glucose, mg/dL (Median, IQR)	124 (102–166)	151 (114–212)	123 (101–164)	<0.001
Creatinine mg/dL (Median, IQR)	1.2 (0.3–9.8)	1.7 (0,3–6,5)	1.1 (0.3–9.8)	<0.001
GFR, mL/min (Median, IQR)	78 (54–95)	39 (22.7–78)	79 (57–95)	<0.001
Na, mg/dL (Mean ± SD)	137.6 ± 4.0	137.3 ± 5.7	137.6 ± 3.9	0.324
K, mg/dL (Mean ± SD)	4.4 ± 0.6	4.7 ± 0.8	4.4 ± 0.6	<0.001
ALT, mg/dL (Median, IQR)	20 (14–32)	24 (12–73)	20 (14–32)	0.001
CRP, mg/dL (Median, IQR)	6 (2–17)	23.6 (10–120)	5.7 (1.9–16)	<0.001
WBC, mg/dL (Mean± SD)	10.0 ± 3.7	12.3 ± 5.3	9.9 ± 3.5	<0.001
Hemoglobin, mg/dL (Mean ± SD)	13.3 ± 2.2	11.9 ± 2.3	13.3 ± 2.2	<0.001
GPR (Mean ± SD)	35.2 ± 18.4	47.0 ± 22.2	35.7 ± 18.7	<0.001

CAD: coronary artery disease; PAD: peripheral artery disease; AF: atrial fibrillation; GFR: glomerular filtration rate; Na: sodium; K: potassium; ALT: alanine aminotransferase; CRP: C-reactive protein; WBC: white blood cell; GPR: glucose potassium ratio; SD: standard deviation.